Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Duality Biotherapeutics, Inc. ( (HK:9606) ) has issued an update.
Duality Biotherapeutics, Inc. has announced an extraordinary general meeting to be held on December 30, 2025, to discuss and potentially approve the 2025 Share Scheme. This scheme involves resolutions for the allotment and issuance of shares under the scheme, which are inter-conditional. The approval of the scheme is contingent upon the Stock Exchange of Hong Kong’s listing approval, which could significantly impact the company’s market operations and shareholder value.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a company incorporated in the Cayman Islands, operating within the biotherapeutics industry. The company focuses on developing innovative therapeutic solutions, with a market emphasis on biopharmaceutical advancements.
Average Trading Volume: 1,365,857
Technical Sentiment Signal: Hold
Current Market Cap: HK$28.99B
Find detailed analytics on 9606 stock on TipRanks’ Stock Analysis page.